OBJECTIVE: To determine the operational effectiveness of the South African programme for preventing mother-to-child transmission (PMTCT) of HIV in reducing rates of early transmission of infection. METHODS: Participants were mother-infant pairs who participated in the South African PMTCT programme between October 2002 and November 2004. This was a prospective cohort study. Three sites in different provinces were selected to represent differences in socioeconomic status and HIV prevalence. Data on antenatal care and labour ward care were obtained from maternal interviews and from reviews of medical records. A total of 665 mother-infant pairs in which the mother was HIV-positive were recruited and 588 (88.4%) were followed up at 3 or 4 weeks postpartum to determine the HIV status and vital status of the infant. FINDINGS: Rural participants were significantly poorer and their health care was significantly worse. Women of higher socioeconomic status and those who received better counselling were more likely to be treated with nevirapine. Rates of early HIV transmission ranged from 8.6% to 13.7%. Maternal viral load was the only statistically significant risk factor for transmission. After adjusting for maternal viral load and prevalence of low birth weight, the odds of transmission were 1.8 times higher at the rural site. Controlling for having had > or = 4 antenatal visits and any delivery complication reduced the odds of transmission to 1.5 higher at the rural site. CONCLUSION: Rates of early transmission of HIV in an operational setting using single-dose nevirapine administered both to mother and child are similar to those obtained in clinical trials. Scaling up access to antiretroviral regimens for women will further reduce transmission to infants.
OBJECTIVE: To determine the operational effectiveness of the South African programme for preventing mother-to-child transmission (PMTCT) of HIV in reducing rates of early transmission of infection. METHODS:Participants were mother-infant pairs who participated in the South African PMTCT programme between October 2002 and November 2004. This was a prospective cohort study. Three sites in different provinces were selected to represent differences in socioeconomic status and HIV prevalence. Data on antenatal care and labour ward care were obtained from maternal interviews and from reviews of medical records. A total of 665 mother-infant pairs in which the mother was HIV-positive were recruited and 588 (88.4%) were followed up at 3 or 4 weeks postpartum to determine the HIV status and vital status of the infant. FINDINGS: Rural participants were significantly poorer and their health care was significantly worse. Women of higher socioeconomic status and those who received better counselling were more likely to be treated with nevirapine. Rates of early HIV transmission ranged from 8.6% to 13.7%. Maternal viral load was the only statistically significant risk factor for transmission. After adjusting for maternal viral load and prevalence of low birth weight, the odds of transmission were 1.8 times higher at the rural site. Controlling for having had > or = 4 antenatal visits and any delivery complication reduced the odds of transmission to 1.5 higher at the rural site. CONCLUSION: Rates of early transmission of HIV in an operational setting using single-dose nevirapine administered both to mother and child are similar to those obtained in clinical trials. Scaling up access to antiretroviral regimens for women will further reduce transmission to infants.
Authors: S Z Wiktor; E Ekpini; J M Karon; J Nkengasong; C Maurice; S T Severin; T H Roels; M K Kouassi; E M Lackritz; I M Coulibaly; A E Greenberg Journal: Lancet Date: 1999-03-06 Impact factor: 79.321
Authors: David Coetzee; Katherine Hilderbrand; Andrew Boulle; Beverley Draper; Fareed Abdullah; Eric Goemaere Journal: Bull World Health Organ Date: 2005-07 Impact factor: 9.408
Authors: L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo Journal: N Engl J Med Date: 1999-08-05 Impact factor: 91.245
Authors: Glenda E Gray; Michael Urban; Matthew F Chersich; Carolyn Bolton; Ronelle van Niekerk; Avy Violari; Wendy Stevens; James A McIntyre Journal: AIDS Date: 2005-08-12 Impact factor: 4.177
Authors: Taha E Taha; Newton I Kumwenda; Donald R Hoover; Susan A Fiscus; George Kafulafula; Chiwawa Nkhoma; Samah Nour; Shu Chen; George Liomba; Paolo G Miotti; Robin L Broadhead Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: D T Dunn; C D Brandt; A Krivine; S A Cassol; P Roques; W Borkowsky; A De Rossi; E Denamur; A Ehrnst; C Loveday Journal: AIDS Date: 1995-09 Impact factor: 4.177
Authors: Ahidjo Ayouba; Eric Nerrienet; Elisabeth Menu; Marcel Monny Lobé; Jocelyn Thonnon; Robert J I Leke; Françoise Barré-Sinoussi; Paul Martin; Patrick Cunin Journal: Am J Trop Med Hyg Date: 2003-10 Impact factor: 2.345
Authors: Sten H Vermund; José A Tique; Holly M Cassell; Megan E Pask; Philip J Ciampa; Carolyn M Audet Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731
Authors: Hillegonda S Hermanides; Lonneke A van Vught; Ralph Voigt; Fred D Muskiet; Aimée Durand; Gerard van Osch; Sharline Koolman-Wever; Isaac Gerstenbluth; Colette Smit; Ashley J Duits Journal: AIDS Res Ther Date: 2011-09-22 Impact factor: 2.250
Authors: Renaud Becquet; Ruth Bland; Valériane Leroy; Nigel C Rollins; Didier K Ekouevi; Anna Coutsoudis; François Dabis; Hoosen M Coovadia; Roger Salamon; Marie-Louise Newell Journal: PLoS One Date: 2009-10-16 Impact factor: 3.240
Authors: Andrew Agabu; Andrew L Baughman; Christa Fischer-Walker; Michael de Klerk; Nicholus Mutenda; Francina Rusberg; Dorothea Diergaardt; Ndumbu Pentikainen; Souleymane Sawadogo; Simon Agolory; Thu-Ha Dinh Journal: PLoS One Date: 2020-11-10 Impact factor: 3.240